On this page
The review in brief
Aspen gives patients a relevant clinical lead and recognizes both standalone and combination options. The public menu leaves the prescription, price and current pharmacy access unresolved. Ask for those details and for a balanced discussion of uncertainty before committing. Broad claims about pharmaceutical quality should not be mistaken for FDA approval of a Semax medication or proof that a specific neurological outcome will occur.
Open the provider record
- Published price
- No current Semax-specific complete price established
- Product description
- Separate Semax and Semax/Selank entries; exact proposed route unresolved
- Access
- Local clinic consultation
In the published record
- Standalone and combination entries are distinct
- Clinical consultation pathway is available
Questions still open
- Current route, package and cost remain unconfirmed
- Broad neurological claims exceed a product-specific outcome
Two entries should stay two entries
Aspen Integrative Medicine lists Semax separately from a Semax/Selank combination. That distinction should survive into any quote or clinical conversation. A blend adds a second intervention; it is not simply a higher tier of the same standalone prescription.
The menu does not identify the final route
The practice discusses injectable and sublingual preparations across its broader menu, but the reviewed Semax entries do not establish a precise current formula and route. Do not turn that general discussion into a specific bottle description. Request the proposed label and the clinical reason for that preparation.
Clinical ambition needs a defined question
The Semax section uses language about cognition, neuroprotection and stroke recovery. These are not equivalent outcomes. A person concerned about ordinary forgetfulness should not interpret a discussion of injury recovery as proof of a useful effect on daily work or learning.
A disease-specific paper stays disease specific
Our spinal-cord mouse study article examines a defined injury model and proposed biological target. It is relevant to the limits of a neuroprotection claim, not evidence that a particular compounded prescription restores human neurological function. The clinician should explain which evidence actually matches the proposed goal.
Compare local care without assuming identical products
The RMRM Boulder review describes another Colorado clinic with Semax on its formulary. Compare the assessment, access and follow-up model before guessing that their products are equivalent. A package quote would need ingredients, route, pharmacy and care costs to support a meaningful financial comparison.
Our assessment
Aspen gives patients a relevant clinical lead and recognizes both standalone and combination options. The public menu leaves the prescription, price and current pharmacy access unresolved. Ask for those details and for a balanced discussion of uncertainty before committing. Broad claims about pharmaceutical quality should not be mistaken for FDA approval of a Semax medication or proof that a specific neurological outcome will occur.
Evidence index
Original research and documented service details.
- Aspen Integrative Medicine official Semax informationCompany website